Saikku P
Dept. of Medical Microbiology, University of Oulu, Oulu, FIN-90014, Finland.
J Infect Dis. 2000 Jun;181 Suppl 3:S411-3. doi: 10.1086/315625.
About 70% of persons with acute myocardial infarction (AMI) show a seroresponse to a chlamydial lipopolysaccharide (LPS) epitope. Elevated titers against Chlamydia pneumoniae in sera from such patients point to an exacerbation in a chronic infection as does a change in the nature of immune complexes containing chlamydial LPS. The presence of antibodies to C. pneumoniae proteins in immune complexes suggests an intimate association of the pathogen with the vascular system. In the first prospective study, elevated antibody titers or immune complexes containing chlamydial LPS were an independent significant risk factor (odds ratio, </=2.6) for AMI 3-6 months before the cardiac incident. The majority of later seroepidemiologic studies have verified the association. However, since serologic markers for C. pneumoniae infection also seem to be associated with uncomplicated atherosclerosis and other chronic conditions, their predictive value for cardiac events is small.
约70%的急性心肌梗死（AMI）患者对衣原体脂多糖（LPS）表位呈血清反应。此类患者血清中抗肺炎衣原体抗体滴度升高，提示慢性感染加剧，含衣原体LPS的免疫复合物性质改变也表明这一点。免疫复合物中存在抗肺炎衣原体蛋白抗体，提示该病原体与血管系统密切相关。在第一项前瞻性研究中，抗体滴度升高或含衣原体LPS的免疫复合物是心脏事件发生前3 - 6个月AMI的独立显著危险因素（比值比，≤2.6）。大多数后续血清流行病学研究证实了这种关联。然而，由于肺炎衣原体感染的血清学标志物似乎也与单纯性动脉粥样硬化和其他慢性疾病有关，它们对心脏事件的预测价值较小。
